Preselection Based on Clinical Characteristics in German Non–Small-Cell Lung Cancer Patients Screened for EML4-ALK Translocation

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Medicine, Oncology, Pharmacology +14

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>

Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson et al. · Journal of Clinical Oncology · 2009 · 1.9K citations · Full text

Medicine, Genetics, Oncology +17

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley et al. · Journal of Thoracic Oncology · 2013 · 1.3K citations · Full text

Medicine, Molecular Medicine, Oncology +17

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

Karen Kelly, John Crowley, Paul A. Bunn et al. · Journal of Clinical Oncology · 2001 · 1.1K citations

Medicine, Oncology, Pharmacology +17